These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9848776

  • 1. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
    Plum J, Bünten B, Németh R, Grabensee B.
    J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
    [Abstract] [Full Text] [Related]

  • 2. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
    Plum J, Bünten B, Németh R, Grabensee B.
    Nephrol Dial Transplant; 1999 Jan; 14 Suppl 4():25-7. PubMed ID: 10463202
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Gotoh A, Uchida K, Higaki J.
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [Abstract] [Full Text] [Related]

  • 7. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 8. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.
    Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE.
    Am J Hypertens; 2003 Dec; 16(12):1030-5. PubMed ID: 14643577
    [Abstract] [Full Text] [Related]

  • 10. Valsartan and the kidney: present and future.
    Mann JF.
    J Cardiovasc Pharmacol; 1999 Dec; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [Abstract] [Full Text] [Related]

  • 11. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy.
    Muirhead N, House A, Hollomby DJ, Jevnikar AM.
    Transplant Proc; 2003 Nov; 35(7):2412-4. PubMed ID: 14611973
    [Abstract] [Full Text] [Related]

  • 12. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans.
    Biggi A, Musiari L, Iori M, De Iaco G, Magnani G, Pelloni I, Pinelli S, Pelà GM, Novarini A, Cabassi A, Montanari A.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):911-6. PubMed ID: 20504911
    [Abstract] [Full Text] [Related]

  • 15. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
    Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H.
    Am J Kidney Dis; 2004 Jun 01; 43(6):1056-64. PubMed ID: 15168386
    [Abstract] [Full Text] [Related]

  • 16. Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
    Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A.
    Kidney Int; 2002 Sep 01; 62(3):885-94. PubMed ID: 12164870
    [Abstract] [Full Text] [Related]

  • 17. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul 01; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 18. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ.
    J Hypertens; 2003 Jan 01; 21(1):209-16. PubMed ID: 12544453
    [Abstract] [Full Text] [Related]

  • 19. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
    Schmitt F, Martinez F, Brillet G, Nguyen-Khoa T, Brouard R, Sissmann J, Lacour B, Grunfeld JP.
    J Cardiovasc Pharmacol; 1998 Feb 01; 31(2):314-21. PubMed ID: 9475275
    [Abstract] [Full Text] [Related]

  • 20. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.